Method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells with microRNA145
The present invention provides a method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells comprising delivering miR145 to the cancer or tumor cells, particularly brain tumor and head and neck cancer cells. The invention further provides a pharmaceutical composition comprising miR145 and a method for treating brain tumor and/or head and neck cancer comprising administration of miR145 to a subject in need thereof.
1. A method for inhibiting cancer stem cell-like and chemoradioresistant properties of glioblastoma multiforme associated cancer stem cells (GBM-CSCs) or head and neck cancer-derived tumor initiating cells (HNC-TICs) comprising delivering miR145 to the GBM-CSCs or HNC-TICs in an amount effective in inhibiting cancer stem cell-like and chemoradioresistant properties of said cells.
2. The method of claim 1 , wherein the miR145 is encapsulated in a polymer as a delivery vehicle.
3. The method of claim 2 , the polymer is a polyurethane (PU).
4. The method of claim 3 , the polyurethane is a synthesized polyurethane (PU) with short branch polyetherimide (sbPEI).
5. The method of claim 1 , wherein the GBM-CSCs are GBM-CD133 + cells and GBM-SF + cells.
6. The method of claim 1 , wherein the HNC-TICs are ALDH1 + , CD44 + , and sphere-forming HNC cells.
7. A method for treating a brain tumor associated with GBM-CSCs comprising administering to a subject in need thereof miR145in an amount effective in inhibiting cancer stem cell-like and chemoradioresistant properties of the GBM-CSCs through a delivery vehicle.
8. The method of claim 7 , the delivery vehicle is a PU.
9. The method of claim 8 , the PU is a synthesized PU-sbPEI.
10. The method of claim 7 , which further comprises treating the subject with radiotherapy or an anti-cancer drug.
11. The method of claim 10 , wherein the anti-cancer drug is temozolomide.
12. The method of claim 7 , wherein the GBM-CSCs are GBM-CD133 + cells and GBM-SF + cells.
13. A method for treating a HNC associated with HNC-TICs comprising administering to a subject in need thereof miR145in an amount effective in inhibiting cancer stem cell-like and chemoradioresistant properties of the HNC-TICs through a delivery vehicle.
14. The method of claim 13 , wherein the miR145 is carried by a vector.
15. The method of claim 14 , wherein the vector is selected from the group consisting of a plasmid, cosmid, phagemid or a virus.
16. The method of claim 13 , wherein the HNC-TICs are ALDH1 + , CD44 + , and sphere-forming HNC cells.